Resveratrol synergizes with cisplatin in antineoplastic effects against AGS gastric cancer cells by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest

Ren,Mengting; Zhou,Xinxin; Gu,Mengli; Jiao,Wenrui; Yu,Mosang; Wang,Yamei; Liu,Sha; Yang,Jinpu; Ji,Feng

doi:10.3892/or.2020.7708

Resveratrol synergizes with cisplatin in antineoplastic effects against AGS gastric cancer cells by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest

Authors:
- Mengting Ren
- Xinxin Zhou
- Mengli Gu
- Wenrui Jiao
- Mosang Yu
- Yamei Wang
- Sha Liu
- Jinpu Yang
- Feng Ji
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: July 31, 2020 https://doi.org/10.3892/or.2020.7708
Pages: 1605-1615
Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is a common gastrointestinal malignancy, and cisplatin (DDP) is an important component of chemotherapeutic regimens for GC. However, the application of DDP is limited by its dose‑dependent systemic toxicity. Resveratrol (RES) is a natural polyphenol compound that has chemopreventive and therapeutic effects against various cancers, including GC. However, whether RES can sensitize GC cells to DDP remains unknown. Following RES/DDP combination treatment, cell viability was determined by Cell Counting Kit‑8 and colony‑forming assays, and cell apoptosis and the cell cycle were detected by FITC‑Annexin V/PI staining assay and PI staining assay, respectively, followed by flow cytometry. Moreover, western blotting was performed to evaluate the protein expression levels, and the intracellular free Ca2+ concentration was determined by a Fluo‑4 AM probe after cell cotreatment with RES and DDP. The present results demonstrated that RES/DDP combination treatment significantly inhibited cell viability, promoted cell apoptosis and induced G2/M phase arrest in AGS cells. In addition, it was determined that RES combined with DDP significantly increased the levels of Bax, cleaved poly‑ADP‑ribose polymerase (PARP), glucose‑regulated protein 78 (GRP78), PRKR‑like ER kinase (PERK), p‑eukaryotic translation initiation factor 2α (p‑eIF2α), CCAAT/enhancer binding protein homologous protein (CHOP) and cleaved caspase‑12, whereas Bcl‑2 expression was downregulated following RES/DDP cotreatment. Moreover, RES/DDP cotreatment significantly upregulated phosphorylated cyclin‑dependent kinase 1 (p‑CDK1, Tyr15), p21Waf1/Cip1 and p27Kip1 protein levels and downregulated Cdc25C protein levels. In conclusion, RES and DDP synergistically inhibited the growth of the gastric adenocarcinoma cell line AGS by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest via activation of the PERK/eIF2α/activating transcription factor 4 (ATF4)/CHOP signaling pathway and caspase‑12 and by inactivating the CDK1‑cyclin B1 complex. These results indicated that RES is a promising adjuvant for DDP during GC chemotherapy.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. Ca Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664. 2016. View Article : Google Scholar : PubMed/NCBI
4	Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, Tang L, Xin Y, Jin J, Zhang YJ, et al: The Chinese society of clinical oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 39:102019. View Article : Google Scholar : PubMed/NCBI
5	Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al: Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 26:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
6	Quintanilha JCF, Saavedra KF, Visacri MB, Moriel P and Salazar LA: Role of epigenetic mechanisms in cisplatin-induced toxicity. Crit Rev Oncol Hematol. 137:131–142. 2019. View Article : Google Scholar : PubMed/NCBI
7	Berman AY, Motechin RA, Wiesenfeld MY and Holz MK: The therapeutic potential of resveratrol: A review of clinical trials. NPJ Precis Oncol. 1:352017. View Article : Google Scholar : PubMed/NCBI
8	Bonnefont-Rousselot D: Resveratrol and cardiovascular diseases. Nutrients. 8:2502016. View Article : Google Scholar
9	Ahmed T, Javed S, Javed S, Tariq A, Šamec D, Tejada S, Nabavi SF, Braidy N and Nabavi SM: Resveratrol and Alzheimers disease: Mechanistic insights. Mol Neurobiol. 54:2622–2635. 2017. View Article : Google Scholar : PubMed/NCBI
10	Nunes S, Danesi F, Del Rio D and Silva P: Resveratrol and inflammatory bowel disease: The evidence so far. Nutr Res Rev. 31:85–97. 2018. View Article : Google Scholar : PubMed/NCBI
11	Wong RHX and Howe PRC: Resveratrol counteracts insulin resistance-potential role of the circulation. Nutrients. 10:11602018. View Article : Google Scholar
12	Jiang Z, Chen K, Cheng L, Yan B, Qian W, Cao J, Li J, Wu E, Ma Q and Yang W: Resveratrol and cancer treatment: Updates. Ann N Y Acad Sci. 1403:59–69. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zulueta A, Caretti A, Signorelli P and Ghidoni R: Resveratrol: A potential challenger against gastric cancer. World J Gastroenterol. 21:10636–10643. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zhou HB, Chen JJ, Wang WX, Cai JT and Du Q: Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol. 11:280–284. 2005. View Article : Google Scholar : PubMed/NCBI
15	Yang Z, Xie Q, Chen Z, Ni H, Xia L, Zhao Q, Chen Z and Chen P: Resveratrol suppresses the invasion and migration of human gastric cancer cells via inhibition of MALAT1-mediated epithelial-to-mesenchymal transition. Exp Ther Med. 17:1569–1578. 2019.PubMed/NCBI
16	Wang M and Kaufman RJ: Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature. 529:326–335. 2016. View Article : Google Scholar : PubMed/NCBI
17	Hetz C and Papa FR: The unfolded protein response and cell fate control. Mol Cell. 69:169–181. 2018. View Article : Google Scholar : PubMed/NCBI
18	Kim C and Kim B: Anti-cancer natural products and their bioactive compounds inducing ER stress-mediated apoptosis: A review. Nutrients. 10:10212018. View Article : Google Scholar
19	Park JW, Woo KJ, Lee JT, Lim JH, Lee TJ, Kim SH, Choi YH and Kwon TK: Resveratrol induces pro-apoptotic endoplasmic reticulum stress in human colon cancer cells. Oncol Rep. 18:1269–1273. 2007.PubMed/NCBI
20	Gwak H, Kim S, Dhanasekaran DN and Song YS: Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells. Cancer Lett. 371:347–353. 2016. View Article : Google Scholar : PubMed/NCBI
21	Heo JR, Kim SM, Hwang KA, Kang JH and Choi KC: Resveratrol induced reactive oxygen species and endoplasmic reticulum stressmediated apoptosis, and cell cycle arrest in the A375SM malignant melanoma cell line. Int J Mol Med. 42:1427–1435. 2018.PubMed/NCBI
22	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
23	Gu ML, Wang YM, Zhou XX, Yao HP, Zheng S, Xiang Z and Ji F: An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells. Oncol Rep. 36:2763–2770. 2016. View Article : Google Scholar : PubMed/NCBI
24	Wang YM, Gu ML, Meng FS, Jiao WR, Zhou XX, Yao HP and Ji F: Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines. Int J Oncol. 51:1860–1868. 2017. View Article : Google Scholar : PubMed/NCBI
25	Bahar E, Kim H and Yoon H: ER stress-mediated signaling: Action potential and ca(2+) as key players. Int J Mol Sci. 17:15582016. View Article : Google Scholar
26	Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J and Unverzagt S: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 8:CD0040642017.PubMed/NCBI
27	Athar M, Back JH, Kopelovich L, Bickers DR and Kim AL: Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys. 486:95–102. 2009. View Article : Google Scholar : PubMed/NCBI
28	Lin SR, Chang CH, Hsu CF, Tsai MJ, Cheng H, Leong MK, Sung PJ, Chen JC and Weng CF: Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence. Br J Pharmacol. 177:1409–1423. 2020. View Article : Google Scholar : PubMed/NCBI
29	Martínez-Martínez D, Soto A, Gil-Araujo B, Gallego B, Chiloeches A and Lasa M: Resveratrol promotes apoptosis through the induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin. Food Chem Toxicol. 124:273–279. 2019. View Article : Google Scholar : PubMed/NCBI
30	Li W, Shi Y, Wang R, Pan L, Ma L and Jin F: Resveratrol promotes the sensitivity of small-cell lung cancer H446 cells to cisplatin by regulating intrinsic apoptosis. Int J Oncol. 53:2123–2130. 2018.PubMed/NCBI
31	Ma L, Li W, Wang R, Nan Y, Wang Q, Liu W and Jin F: Resveratrol enhanced anticancer effects of cisplatin on non-small cell lung cancer cell lines by inducing mitochondrial dysfunction and cell apoptosis. Int J Oncol. 47:1460–1468. 2015. View Article : Google Scholar : PubMed/NCBI
32	Liu Z, Peng Q, Li Y and Gao Y: Resveratrol enhances cisplatin-induced apoptosis in human hepatoma cells via glutamine metabolism inhibition. BMB Rep. 51:474–479. 2018. View Article : Google Scholar : PubMed/NCBI
33	Cubillos-Ruiz JR, Bettigole SE and Glimcher LH: Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell. 168:692–706. 2017. View Article : Google Scholar : PubMed/NCBI
34	Corazzari M, Gagliardi M, Fimia GM and Piacentini M: Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate. Front Oncol. 7:782017. View Article : Google Scholar : PubMed/NCBI
35	Limonta P, Moretti RM, Marzagalli M, Fontana F, Raimondi M and Montagnani Marelli M: Role of endoplasmic reticulum stress in the anticancer activity of natural compounds. Int J Mol Sci. 20:9612019. View Article : Google Scholar
36	Urra H, Dufey E, Avril T, Chevet E and Hetz C: Endoplasmic reticulum stress and the hallmarks of cancer. Trends Cancer. 2:252–262. 2016. View Article : Google Scholar : PubMed/NCBI
37	Rao RV, Ellerby HM and Bredesen DE: Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ. 11:372–380. 2004. View Article : Google Scholar : PubMed/NCBI
38	Gu S, Chen C, Jiang X and Zhang Z: ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction underlie apoptosis induced by resveratrol and arsenic trioxide in A549 cells. Chem Biol Interact. 245:100–109. 2016. View Article : Google Scholar : PubMed/NCBI
39	Chow SE, Kao CH, Liu YT, Cheng ML, Yang YW, Huang YK, Hsu CC and Wang JS: Resveratrol induced ER expansion and ER caspase-mediated apoptosis in human nasopharyngeal carcinoma cells. Apoptosis. 19:527–541. 2014. View Article : Google Scholar : PubMed/NCBI
40	Otto T and Sicinski P: Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115. 2017. View Article : Google Scholar : PubMed/NCBI
41	Shin KO, Park NY, Seo CH, Hong SP, Oh KW, Hong JT, Han SK and Lee YM: Inhibition of sphingolipid metabolism enhances resveratrol chemotherapy in human gastric cancer cells. Biomol Ther (Seoul). 20:470–476. 2012. View Article : Google Scholar : PubMed/NCBI
42	Suttie SA, Park KG and Smith TA: [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. Br J Cancer. 97:902–909. 2007. View Article : Google Scholar : PubMed/NCBI
43	Satyanarayana A and Kaldis P: Mammalian cell-cycle regulation: Several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene. 28:2925–2939. 2009. View Article : Google Scholar : PubMed/NCBI
44	Perdiguero E and Nebreda AR: Regulation of Cdc25C activity during the meiotic G2/M transition. Cell Cycle. 3:733–737. 2004. View Article : Google Scholar : PubMed/NCBI
45	Hu X and Moscinski LC: Cdc2: A monopotent or pluripotent CDK? Cell Prolif. 44:205–211. 2011. View Article : Google Scholar : PubMed/NCBI
46	Berridge MJ: Inositol trisphosphate and calcium signalling. Nature. 361:315–325. 1993. View Article : Google Scholar : PubMed/NCBI